Nutcracker Therapeutics’ Post

👉 Conference Alert! I will be happy to meet you at #ADLM and talk about how you can use our solutions in your lab!

🔥NOTE: CAR-T cells using DNA technology can cause CAR-T lymphomas! Is it worth it to give these to autoimmune disease patients? We should probably stick to technologies that will not cause CAR-T lymphomas: 👉RNA CAR-T cells (like Cartesian Therapeutics Descartes-08) ... they do not replicate in the patient's body 👉Chimeric autoantigen T-cell receptor (CATCR) T-cell therapies (as used in a recent Johns Hopkins study) 👉CAART therapies (like that from Cabaletta Bio ) Read more about these therapies here: https://lnkd.in/gsYDqfhj Or click on the link below my picture here: https://lnkd.in/g__iquKm @talkmedspoke

Our clinical trial for ST-001 is making progress with more patients joining in! If you're interested in learning more about our trial and locations for T-cell non-Hodgkin's lymphoma (NHL), click here: https://lnkd.in/edqpS-5E. Our current drug formulation utilizes a phospholipid suspension of nanoparticle-sized fenretinide, aiming to overcome previous absorption limitations. In this Phase 1 trial for relapsed/refractory T-cell NHL, we're evaluating the safety profile, pharmacology, and maximum tolerated dose of ST-001. Targeted indications include various T-cell NHL subtypes like cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and more. Stay tuned for updates as we advance in our mission to improve treatments for T-cell NHL! #ClinicalTrials #NHLResearch

Labcorp® Plasma Focus™ is an actionable liquid biopsy test for therapy selection with a clear report that focuses on FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers. Learn more about Labcorp Plasma Focus.

Labcorp® Plasma Focus™ is an actionable liquid biopsy test for therapy selection with a clear report that focuses on FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers. Learn more about Labcorp Plasma Focus.

HER2 is a tumor-associated antigen commonly overexpressed on a subset of breast cancers and gastric/gastroesophageal cancers. Immunotherapies targeting HER2 have improved clinical outcomes. We offer a variety of HER2 humanized mouse models to evaluate preclinical efficacy and toxicity of novel HER2-targeting therapeutic candidates. Check out our B-hHER2 mice (https://lnkd.in/ebgM7saN) and B-h4-1BB/hHER2 mice (https://lnkd.in/emTrjaRV). #mousemodel #tumormodel #immunecheckpoint #humanizedmodel #preclinicalresearch #invivo #therapeutics #immunotherapy #antitumortherapy #cancertherapy #cancerresearch

Labcorp® Plasma Focus™ is an actionable liquid biopsy test for therapy selection with a clear report that focuses on FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers. Learn more about Labcorp Plasma Focus.

Labcorp® Plasma Focus™ is an actionable liquid biopsy test for therapy selection with a clear report that focuses on FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers. Learn more about Labcorp Plasma Focus.

Labcorp® Plasma Focus™ is an actionable liquid biopsy test for therapy selection with a clear report that focuses on FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers. Learn more about Labcorp Plasma Focus.

Follicular lymphoma poses a significant challenge due to its relapsing nature and limited treatment options, particularly for patients with early progression or refractory disease. According to DelveInsight estimates, approximately 37,000 cases of follicular lymphoma were reported in the US in 2023. TQ-B3525, a novel oral PI3K α/δ inhibitor developed in China, offers a potential solution to this dilemma. By targeting both PI3K catalytic subunits α and δ, TQ-B3525 addresses drug resistance issues and minimizes toxic side effects, presenting a valuable therapeutic option. Unlock In-Depth Expert Insights and Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Reporting @ https://lnkd.in/g5-Qkrpr #FollicularLymphoma #cancer #treatmentoptions #relapse #refractorydisease #PI3Kinhibitor #TQB3525 #drugresistance #China #oncology #cancerresearch #clinicaltrials #pharmaceuticals #healthcare #patientcare